CIRIUM
10.11.2021 09:02:15 CET | Business Wire | Press release
Cirium, the aviation analytics company, today launched its Global Aircraft Emissions Monitor, providing a highly accurate measure of CO2 emissions and fuel consumption from flights flown globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005600/en/
New insights from Cirium show that airlines have burnt 40% less fuel from flights in 2021 year-to-date compared to the same period in 2019.
The reduction in flight-produced carbon emissions is attributed to the drop in flights worldwide because of the dramatic impact that COVID-19 had on air travel. Flights tracked year-to-date are 29% down versus 2019.
The fuel burn has increased as domestic and international flights have started to return but not as much as expected compared to 2019—before the pandemic. The airlines have been flying their aircraft far fewer hours and prioritizing more efficient aircraft.
“To achieve the aggressive targets for aviation to reach net zero emissions by 2050, a thorough understanding is needed of all elements of an aircraft used for flights and the exact flight operations,” said Jeremy Bowen, CEO at Cirium.
“Cirium’s Global Aircraft Emissions Monitor boasts data of the highest quality and validity. The need for greater sustainability is clear and Cirium is committed to supporting the industry’s decision-making based on accurate carbon emissions tracking.”
The uniqueness of the product derives from the data, which is obtained from the widest and deepest data warehouse in the aviation industry. No other independent source can provide calculations based on the same blended data sets. The Monitor’s custom data calculations are based on hundreds of flight and aircraft variables for maximum accuracy. These variables include actual flight and taxi times, cabin configuration, aircraft operating empty weight, assumed cargo tonnage, aircraft/engine type, winglet equipage, aircraft age and more.
Tests conducted on the Global Aircraft Emissions Monitor have validated its accuracy in the order of 1%.
The Global Aircraft Emissions Monitor includes customized options for CO2 emissions and fuel consumption. It applies complete profiles of actual flights and aircraft, which are fused with block fuel burn models.
While aviation has reduced its emissions overall this year, travel is recovering, with Cirium forecasts projecting for global recovery to 2019 levels potentially by 2023. Cirium’s Fleet Forecast also predicts that based on the flight capacity of the increasing fleet to be in service by 2039, fuel burn may reach 485 million tons. This equates to 1,530 million tons of CO2 emissions, excluding any initiatives for sustainable aviation fuels (SAF) or offsetting.
Carbon emissions and fuel consumption from flights are increasingly becoming the centre focus for all airlines, airports aviation finance, aircraft manufacturers, air traffic management, government, and fuel providers.
The comprehensiveness of the Cirium Global Aircraft Emissions Monitor will enable organizations to track emissions as a measure of efficiency, understand aspects of total cost of ownership, understand the profile of a current operator, gain a better understanding of the climate impact, benchmark the competition, and create fuel demand models.
Find out more at https://cirium.com/EmissionsMonitor .
-End-
For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005600/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
